Mesothelin is a surface antigen present on human meningioma and can be effectively targeted by CAR T-cells

间皮素 抗原 脑膜瘤 生物 免疫学 医学 病理
作者
Rishab Ramapriyan,Fred G. Barker,Leland G. Richardson,Jing Sun,Gust Vandecandelaere,Jane M Shim,Guillaume De Vlaminck,Matthew Gaffey,Eric P. Grewal,Masih Tazhibi,Kourosh Morshedy,Amir Reza Aref,Syeda Maheen Batool,Xiaopeng Guo,Nazanin Ijad,Leonora Balaj,Hiroaki Wakimoto,Maria Martinez‐Lage,Matthew J. Frigault,Mark B. Leick
出处
期刊:Neuro-oncology [Oxford University Press]
卷期号:27 (12): 3104-3118 被引量:5
标识
DOI:10.1093/neuonc/noaf155
摘要

BACKGROUND: Meningioma is the most common primary CNS tumor, with high-grade cases exhibiting aggressive behavior, frequent recurrence, and poor prognosis. Currently, no systemic therapies are approved for recurrent or malignant meningiomas. Chimeric antigen receptor (CAR) T-cell therapy has shown efficacy in hematologic malignancies and promise for solid tumors, but its use for meningiomas has been underexplored. Mesothelin, a glycoprotein overexpressed in several solid tumors of mesodermal origin, may serve as a viable immunotherapeutic target. This study aimed to evaluate mesothelin as a CAR T-cell target in meningiomas. METHODS: Mesothelin expression was analyzed in patient-derived meningioma samples using immunohistochemistry, flow cytometry, and droplet digital PCR. Mesothelin-specific CAR T-cells were generated and evaluated invitro, exvivo using patient-derived organotypic tumor spheroids (PDOTS), and invivo using orthotopic meningioma mouse models of human xenografts. Cytotoxicity, T-cell proliferation, cytokine secretion, and tumor clearance were assessed. RESULTS: Mesothelin was detected in a subset of tumors across all meningioma grades at the transcript and protein levels, with surface expression confirmed in patient-derived primary cells. Mesothelin-specific CAR T-cells exhibited potent and specific cytotoxicity, T-cell activation, and cytokine secretion in vitro and effectively eliminated PDOTS. In orthotopic human xenograft models, mesothelin CAR T-cell therapy led to significant tumor regression and prolonged survival. CONCLUSIONS: Mesothelin is a viable CAR T-cell target for meningiomas, and mesothelin-specific CAR T-cell therapy shows strong preclinical efficacy. These findings provide a rationale for early-phase clinical trials of mesothelin CAR T-cell therapy in patients with refractory meningiomas.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
675675发布了新的文献求助10
3秒前
汉堡包的应助被小艾同学采纳,获得10
3秒前
4秒前
7秒前
11NING完成签到,获得积分10
7秒前
7秒前
SCI完成签到,获得积分10
8秒前
Koi发布了新的文献求助10
8秒前
禹hs完成签到,获得积分10
11秒前
吱ing完成签到 ,获得积分10
12秒前
ding的应助被bbb采纳,获得10
12秒前
SCI发布了新的文献求助10
12秒前
ZeSheng完成签到,获得积分10
13秒前
14秒前
14秒前
14秒前
眠龙完成签到 ,获得积分10
15秒前
猪猪侠完成签到,获得积分10
16秒前
16秒前
16秒前
英俊的铭的应助被xxx采纳,获得10
17秒前
水煮电吹风的应助被叶95采纳,获得10
17秒前
ylfs完成签到,获得积分10
17秒前
18秒前
bobo完成签到,获得积分10
19秒前
小艾同学发布了新的文献求助10
19秒前
see发布了新的文献求助10
20秒前
在水一方的应助被LILILILI采纳,获得30
21秒前
嘤嘤嘤完成签到,获得积分10
21秒前
21秒前
999完成签到,获得积分10
21秒前
123完成签到 ,获得积分10
22秒前
香蕉觅云的应助被祥子的骆驼采纳,获得10
23秒前
。。。完成签到,获得积分0
25秒前
自然思烟完成签到,获得积分10
26秒前
bbb发布了新的文献求助10
28秒前
冷酷以山发布了新的文献求助10
28秒前
anders完成签到 ,获得积分10
30秒前
进化又不带我完成签到 ,获得积分10
30秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181658
求助须知:如何正确求助?哪些是违规求助? 9571454
关于积分的说明 21818081
捐赠科研通 7777987
什么是DOI,文献DOI怎么找? 3433508
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479568